23andMe is helping collaborators better understand disease biology, identify novel targets, boost clinical trial success, and engage people in their care SUNNYVALE, Calif. and LONDON, Jan. 08, 2025 ...
The assets of failed DNA testing firm 23andMe are being bought for $256 million. Biotechnology firm Regeneron Pharmaceuticals said on Monday it would acquire 23andMe's personal genome service, total ...
Beleaguered genetic testing company 23andMe announced Friday that it has reached an agreement to sell itself to a nonprofit led by the company’s co-founder and former CEO, Anne Wojcicki. Following a ...
David Siffert, legal director at S.T.O.P., discusses 23andMe’s possible bankruptcy along with the potential legal fallout and the privacy threat it poses to our genetic data. By now, multiple sources ...
23andMe files for bankruptcy, says data privacy will be ‘important consideration’ if company is sold
23andMe has filed for Chapter 11 bankruptcy protection and its co-founder and CEO has resigned as the struggling genetic testing company continues its push to cut costs. San Francisco-based 23andMe ...
Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing company filed for Chapter 11 bankruptcy protection. In March 23andMe said that ...
NEW YORK — 23andMe has filed for Chapter 11 bankruptcy protection and its co-founder and CEO has resigned as the struggling genetic testing company continues its push to cut costs. San Francisco-based ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results